EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

• Published in: Nature cell biology Vol. 24; no. 3; pp. 384 - 399
• Main Authors: Wang, Jun, Yu, Xufen, Gong, Weida, Liu, Xijuan, Park, Kwang-Su, Ma, Anqi, Tsai, Yi-Hsuan, Shen, Yudao, Onikubo, Takashi, Pi, Wen-Chieh, Allison, David F, Liu, Jing, Chen, Wei-Yi, Cai, Ling, Roeder, Robert G, Jin, Jian, Wang, Gang Greg
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.03.2022
• Subjects: Anticancer properties; Binding; Cancer; Carcinogenesis - genetics; Cytoskeletal Proteins - metabolism; Depletion; Domains; E1A-Associated p300 Protein; Enhancer of Zeste Homolog 2 Protein - genetics; Enhancer of Zeste Homolog 2 Protein - metabolism; Gene silencing; Humans; Inhibitors; Kinases; Leukemia; Neoplasms; Proteolysis; Transcriptional Activation; Tumorigenesis; Tumors

Canonically, EZH2 serves as the catalytic subunit of PRC2, which mediates H3K27me3 deposition and transcriptional repression. Here, we report that in acute leukaemias, EZH2 has additional noncanonical functions by binding cMyc at non-PRC2 targets and uses a hidden transactivation domain (TAD) for (c...